美国食品和药物管理局批准UNLOXCYT用于晚期皮肤癌的成年人, FDA approves UNLOXCYT for adults with advanced skin cancer, offering new treatment option.

美国FDA批准Checkpoint Therapeutics公司的UNLOXCYT (cosibelimab- ipdl) 用于治疗成年人转移性或局部发达的皮肤状细胞癌 (cSCC),这些患者不能接受治疗性手术或放射治疗. The U.S. FDA has approved UNLOXCYT (cosibelimab-ipdl) by Checkpoint Therapeutics for treating adults with metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) who cannot undergo curative surgery or radiation. 这使UNLOXCYT成为第一个由林业发展局批准的PD-L1阻塞抗体,用于这一条件。 This makes UNLOXCYT the first FDA-approved PD-L1 blocking antibody for this condition. 药物每三周静脉注射一次。 The drug is administered intravenously every three weeks.